Connect your AI

ADMA Biologics ADMA Change in Other Assets

Change in Other Assets at other companies

AbCellera Biologics Inc.ABCL

$1.74M+124%

AnaptysBio, Inc.ANAB

-$1.5M-183%

ZymeworksZYME

$1.73M+160%

Apogee Therapeutics, Inc.APGE

-$155K-102%

BiohavenBHVN

-$12.56M-274%

AmgenAMGN

-$8M-104%

Other financials

Income statement

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ADMA Biologics's change in other assets?: ADMA Biologics (ADMA) reported change in other assets of $1.6M in Q1 2026.
How has ADMA Biologics's change in other assets changed year-over-year?: ADMA Biologics's change in other assets decreased by 38.3% year-over-year, from $2.6M to $1.6M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.